OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions
Syona S Shetty, Andrew Krumerman
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 12
Syona S Shetty, Andrew Krumerman
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 12
Showing 12 citing articles:
SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study
Jiang Li, Yuefeng Yu, Ying Sun, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 26
Jiang Li, Yuefeng Yu, Ying Sun, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 26
The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review
Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5408-5408
Open Access | Times Cited: 9
Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5408-5408
Open Access | Times Cited: 9
Sodium–glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis
Hongda Zhang, Lei Ding, Lijie Mi, et al.
European Journal of Preventive Cardiology (2023) Vol. 31, Iss. 7, pp. 770-779
Closed Access | Times Cited: 21
Hongda Zhang, Lei Ding, Lijie Mi, et al.
European Journal of Preventive Cardiology (2023) Vol. 31, Iss. 7, pp. 770-779
Closed Access | Times Cited: 21
Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101390-101390
Closed Access | Times Cited: 22
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101390-101390
Closed Access | Times Cited: 22
Benefits of SGLT2 inhibitors in arrhythmias
Jinghan Gao, Genlong Xue, Ge Zhan, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 21
Jinghan Gao, Genlong Xue, Ge Zhan, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 21
Empagliflozin to prevent post‐operative atrial fibrillation in patients undergoing coronary artery bypass graft surgery
Maryam Aghakouchakzadeh, Kaveh Hosseini, Majid Haghjoo, et al.
Pacing and Clinical Electrophysiology (2024) Vol. 47, Iss. 8, pp. 1087-1095
Closed Access | Times Cited: 2
Maryam Aghakouchakzadeh, Kaveh Hosseini, Majid Haghjoo, et al.
Pacing and Clinical Electrophysiology (2024) Vol. 47, Iss. 8, pp. 1087-1095
Closed Access | Times Cited: 2
The role of interleukins in pathogenesis and prognosis of atrial fibrillation
Mohammad Lotfi, Parmida Sadat Pezeshki, Nima Rezaei
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 6, pp. 585-597
Open Access | Times Cited: 6
Mohammad Lotfi, Parmida Sadat Pezeshki, Nima Rezaei
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 6, pp. 585-597
Open Access | Times Cited: 6
SGLT2 Inhibitors and Catheter Ablation for Atrial Fibrillation
Peter Calvert, Dhiraj Gupta, Riccardo Proietti
JACC. Clinical electrophysiology (2023) Vol. 9, Iss. 10, pp. 2119-2121
Closed Access | Times Cited: 2
Peter Calvert, Dhiraj Gupta, Riccardo Proietti
JACC. Clinical electrophysiology (2023) Vol. 9, Iss. 10, pp. 2119-2121
Closed Access | Times Cited: 2
Effects of sodium-glucose cotransporter-2 inhibitor on atrial high-rate episodes in patients with cardiovascular implantable electronic device: a randomized controlled trial
Teerapat Nantsupawat, Nattayaporn Apaijai, Arintaya Phrommintikul, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Teerapat Nantsupawat, Nattayaporn Apaijai, Arintaya Phrommintikul, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Sodium-Glucose Co-Transporter 2 Inhibitor Use in Type II Diabetes Mellitus is Associated with a Lower Rate of Atrial Arrhythmias in a Hospitalized Real-World Population
Kathryn Tiver, Derek P. Chew, Ju Tan, et al.
Heart Rhythm O2 (2024) Vol. 6, Iss. 3, pp. 299-306
Open Access
Kathryn Tiver, Derek P. Chew, Ju Tan, et al.
Heart Rhythm O2 (2024) Vol. 6, Iss. 3, pp. 299-306
Open Access
Les inhibiteurs des SGLT2 réduisent le risque de fibrillation auriculaire, d’arythmies ventriculaires et de mort subite
André Scheen
Médecine des Maladies Métaboliques (2022)
Closed Access | Times Cited: 1
André Scheen
Médecine des Maladies Métaboliques (2022)
Closed Access | Times Cited: 1
Evolución clínica de los pacientes con FA y diabetes mellitus en la pandemia de COVID-19. Registro REFADI
Gonzalo Barón‐Esquivias, Iris Esteve‐Ruiz, Silvia Gómez-Moreno, et al.
REC CardioClinics (2023) Vol. 58, Iss. 3, pp. 190-198
Closed Access
Gonzalo Barón‐Esquivias, Iris Esteve‐Ruiz, Silvia Gómez-Moreno, et al.
REC CardioClinics (2023) Vol. 58, Iss. 3, pp. 190-198
Closed Access
